Clinical Trial

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of Vespireit, prolonged-release tablets, 15 mg (Valenta Pharm JSC, Russia) in comparison with Arlevert, tablets, 40 mg + 20 mg (Menarini International Operations Luxembourg S.A., Luxembourg) in patients with autonomic dysfunction syndrome accompanied by functional vertigo.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-13.
Trial Details
NCT Number NCT06321341
Lead Sponsor Valenta Pharm JSC
Conditions Vertigo, Autonomic Dysfunction
Enrollment 160 participants
Start Date 2024-01-24
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-15